Zacks Investment Research downgraded shares of Zafgen (NASDAQ:ZFGN) from a buy rating to a hold rating in a report published on Saturday.

According to Zacks, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. “

Separately, ValuEngine raised Zafgen from a strong sell rating to a sell rating in a report on Monday, October 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $6.63.

Shares of Zafgen (NASDAQ ZFGN) traded down $0.04 during trading on Friday, reaching $5.56. 111,654 shares of the company’s stock traded hands, compared to its average volume of 155,300. Zafgen has a one year low of $3.21 and a one year high of $5.75.

Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.12. equities research analysts anticipate that Zafgen will post -2.02 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of ZFGN. GSA Capital Partners LLP acquired a new stake in shares of Zafgen in the second quarter valued at approximately $259,000. OxFORD Asset Management LLP acquired a new stake in shares of Zafgen in the second quarter valued at approximately $364,000. Goldman Sachs Group Inc. boosted its holdings in shares of Zafgen by 1,701.5% in the second quarter. Goldman Sachs Group Inc. now owns 197,287 shares of the biopharmaceutical company’s stock valued at $692,000 after acquiring an additional 186,336 shares during the period. Mangrove Partners acquired a new stake in shares of Zafgen in the third quarter valued at approximately $1,971,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Zafgen by 31.8% in the second quarter. Dimensional Fund Advisors LP now owns 584,159 shares of the biopharmaceutical company’s stock valued at $2,050,000 after acquiring an additional 140,848 shares during the period. 48.60% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Zafgen (ZFGN) Downgraded by Zacks Investment Research” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.watchlistnews.com/zafgen-zfgn-downgraded-by-zacks-investment-research/1806977.html.

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Get a free copy of the Zacks research report on Zafgen (ZFGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.